Roche debuts new MedTech for needle-free management of Diabetes

30/05/2016 - 2 minutes

Roche is making progress in its Diabetes Care unit. It has struck a deal with the MedTech company Senseonics to sell an implantable glucose sensor in some major European countries.

roche_diabetes_care_medtech_senseonicsThe Diabetes Care division of Swiss big Pharma Roche has more than 35 years of experience, and its Accu-Check devices are one of best-selling diabetes management systems in the world.

Roche is now expanding its product portfolio with Eversense, a continuous glucose monitoring (CGM) system from Senseonics (Maryland, US).

Roche struck a deal for exclusive distribution of Senseonics’ technology in Germany, Italy and the Netherlands – with the option to extend to other European countries.

Roche will also be responsible for sales, marketing and customer support, while Senseonics retains responsibility for product development and manufacturing.

Eversense is Senseonics’ first diabetes management system, and includes a small sensor, a smart transmitter and a mobile App.

Related Content

Another example of the needle-free trend in glucose monitoring,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member